(Q37644480)

21 August 2017

1 reference

title

Toward more efficient clinical trials for amyotrophic lateral sclerosis (English)

1 reference

amyotrophic lateral sclerosis

21 August 2017

main subject

0 references

9

Karl Kieburtz

1 reference

21 August 2017

6

Hiroshi Mitsumoto

1 reference

21 August 2017

1

Merit E Cudkowicz

1 reference

21 August 2017

7

Stanley Appel

1 reference

21 August 2017

10

Ira Shoulson

1 reference

21 August 2017

Jon Katz

2

1 reference

21 August 2017

Dan H Moore

3

1 reference

21 August 2017

Gilmore O'Neill

4

1 reference

21 August 2017

Jonathan D Glass

5

1 reference

21 August 2017

Bernard Ravina

8

1 reference

21 August 2017

Petra Kaufmann

11

1 reference

21 August 2017

Jaffar Khan

12

1 reference

21 August 2017

Ericka Simpson

13

1 reference

21 August 2017

Jeremy Shefner

14

1 reference

21 August 2017

Bruce Levin

15

1 reference

21 August 2017

Valerie Cwik

16

1 reference

21 August 2017

David Schoenfeld

17

1 reference

21 August 2017

Swati Aggarwal

18

1 reference

21 August 2017

Michael P McDermott

19

1 reference

21 August 2017

Robert G Miller

20

1 reference

21 August 2017

publication date

1 May 2010

1 reference

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

21 August 2017

published in

1 reference

21 August 2017

volume

11

1 reference

21 August 2017

issue

3

1 reference

21 August 2017

page(s)

259-265

1 reference

Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F17482960903358865

PTC124 targets genetic disorders caused by nonsense mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482960903358865

Impact of amyloid imaging on drug development in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482960903358865

Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482960903358865

Predictive Probability Early Termination Plans For Phase II Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482960903358865

A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482960903358865

A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482960903358865

A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482960903358865

A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482960903358865

Design of phase II ALS clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482960903358865

Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482960903358865

Phase II/III randomized trial of TCH346 in patients with ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482960903358865

Lithium delays progression of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482960903358865

A clinical trial of creatine in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482960903358865

Subcutaneous IGF-1 is not beneficial in 2-year ALS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482960903358865

10.3109/17482960903358865

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference